NASDAQ:EVAX Evaxion A/S (EVAX) Stock Price, News & Analysis $3.25 +0.15 (+4.84%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.24 0.00 (-0.15%) As of 08/22/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evaxion A/S Stock (NASDAQ:EVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evaxion A/S alerts:Sign Up Key Stats Today's Range$3.10▼$3.2950-Day Range$2.07▼$3.2552-Week Range$1.20▼$17.75Volume74,198 shsAverage Volume126,617 shsMarket Capitalization$4.55 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. Read More Evaxion A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreEVAX MarketRank™: Evaxion A/S scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvaxion A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvaxion A/S has received no research coverage in the past 90 days.Read more about Evaxion A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Evaxion A/S are expected to decrease in the coming year, from ($0.15) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion A/S is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion A/S is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvaxion A/S has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Evaxion A/S's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.42% of the float of Evaxion A/S has been sold short.Short Interest Ratio / Days to CoverEvaxion A/S has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion A/S has recently increased by 12.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvaxion A/S does not currently pay a dividend.Dividend GrowthEvaxion A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.42% of the float of Evaxion A/S has been sold short.Short Interest Ratio / Days to CoverEvaxion A/S has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion A/S has recently increased by 12.73%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.67 News SentimentEvaxion A/S has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evaxion A/S this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for EVAX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Evaxion A/S to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evaxion A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.04% of the stock of Evaxion A/S is held by institutions.Read more about Evaxion A/S's insider trading history. Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address EVAX Stock News HeadlinesEvaxion Biotech A/S (NASDAQ:EVAX) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | msn.comEvaxion A/S (EVAX) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | seekingalpha.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)Evaxion Biotech Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comInsights Ahead: Evaxion Biotech's Quarterly EarningsAugust 14, 2025 | benzinga.comEvaxion announces business update and second quarter 2025 financial resultsAugust 14, 2025 | finance.yahoo.comEvaxion A/S Reports Q2 2025 Financials and Strategic ProgressAugust 14, 2025 | msn.comEvaxion to announce business update and second quarter 2025 financial results on August 14, 2025August 11, 2025 | globenewswire.comSee More Headlines EVAX Stock Analysis - Frequently Asked Questions How have EVAX shares performed this year? Evaxion A/S's stock was trading at $4.2270 on January 1st, 2025. Since then, EVAX shares have decreased by 23.1% and is now trading at $3.25. How were Evaxion A/S's earnings last quarter? Evaxion A/S - Sponsored ADR (NASDAQ:EVAX) released its earnings results on Thursday, August, 14th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.26. The business earned $0.04 million during the quarter. Evaxion A/S had a negative net margin of 316.03% and a negative trailing twelve-month return on equity of 319.52%. Read the conference call transcript. When did Evaxion A/S's stock split? Evaxion A/S's stock reverse split before market open on Monday, January 13th 2025.The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did Evaxion A/S IPO? Evaxion A/S (EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Evaxion A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evaxion A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML). Company Calendar Last Earnings8/14/2025Today8/24/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVAX CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Evaxion A/S$10.00 High Price Target$14.00 Low Price Target$6.00 Potential Upside/Downside+207.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.57 million Net Margins-316.03% Pretax Margin-400.88% Return on Equity-319.52% Return on Assets-63.56% Debt Debt-to-Equity Ratio1.73 Current Ratio3.42 Quick Ratio2.01 Sales & Book Value Annual Sales$3.34 million Price / Sales1.36 Cash FlowN/A Price / Cash FlowN/A Book Value$4.44 per share Price / Book0.73Miscellaneous Outstanding Shares1,400,000Free Float819,000Market Cap$4.55 million OptionableNo Data Beta0.13 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:EVAX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.